Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)

Stopped The trial was intended to be a Phase 1/2 trial, but the sponsor terminated the trial prior to moving to Phase 2 to direct efforts to the pediatric study (ARYA-2) for this product.

Conditions

• Hepatocellular Carcinoma
• Liver Cancer
• Liver Neoplasm
• Metastatic Liver Cancer

Interventions

• BIOLOGICAL: ET140203 autologous T cell product

Sponsor

Eureka Therapeutics Inc.